Treatment of Allergic Patients with Adenotonsillar Hypertrophy: Surgery Versus Medication Therapy

  • Mahnaz Sadeghi Shabestari Immunology Research Center, TB and Lung Disease Research Center of Tabriz, Children Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  • Yalda Jabbari Moghaddam Department of Otorhinolaryngology, School of Medicine, Sina Medical Research and Training Hospital, Children Medical Research and Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  • Navid Kalani Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
  • Fariborz Brumdanpur Department of Otorhinolaryngology, School of Medicine, Sina Medical Research and Training Hospital, Children Medical Research and Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  • Amin Dakhili Ardestani Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran
  • Mojtaba Sohrabpour Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
Keywords: Allergic, Adenotonsillar Hypertrophy, Medication, Tonsillectomy


Background: Adenotonsillar hypertrophy (AH) is the most common cause of respiratory obstruction of the upper airway, and tonsillectomy is one of the most frequently performed surgical interventions in children. It has been proposed that medical treatment in an allergic state could decrease the size of AH. Therefore, this study aimed to compare the outcomes of surgery and medical therapies among allergic children with AH. Materials and Methods: This case-control study was carried out on 68 children with AH in an allergic state who were referred to the Pediatrics Hospital of Tabriz Medical University. They were divided into two groups and matched according to sex, age, and primary clinical signs and symptoms. Patients received surgery (case group) and medication (control groups) for treated AH. Finally, they were compared according to the results of treatment and recurrence rate. Results: The mean age of children in the case and control groups was 6.3±2.3 and 6.8±2.1 years, respectively. There was no significant difference in improving clinical signs and symptoms between the two groups. In the case group, no improvement of clinical signs and symptoms was observed in one patient compared with two patients in the control group. In the control group, no decrease in the size of the tonsils was observed in three patients. Recurrence of clinical signs of AH was observed in six (17.6%) patients of the control group, and there was a significant difference between the two groups (P<0.001). Conclusion: Our findings showed no significant differences in the outcomes of the two therapeutic methods for AH in an allergic state. However, medical treatment needs a long time to affect, but surgery can act quickly. Recurrence of AH after medical therapy could occur.


Brambilla I, Pusateri A, Pagella F, Caimmi D, Caimmi S, Licari A, et al. Adenoids in children: advances in immunology, diagnosis, and surgery. Clin Anat. 2014;27(3):346-52.


Brambilla I, Manti S, Savasta S, Valsecchi C, Caimmi SM, Marseglia GL, et al. Adenoidal Immune Response in the Context of Inflammation and Allergy. Current Respiratory Medicine Reviews. 2019;15(3):231-7.

Buskens E, Van Staaij B, Van Den Akker J, Hoes AW, Schilder AG. Adenotonsillectomy or watchful waiting in patients with mild to moderate symptoms of throat infections or adenotonsillar hypertrophy: a randomized comparison of costs and effects. Arch Otolaryngol Head Neck Surg. 2007;133(11):1083-8.


Shen L, Zheng B, Lin Z, Xu Y, Yang Z. Tailoring therapy to improve the treatment of children with obstructive sleep apnea according to grade of adenotonsillar hypertrophy. Int J Pediatr Otorhinolaryngol. 2015;79(4):493-8.


Colavita L, Miraglia MDG, Stroscio G, Visalli C, Alterio T, Pidone C, et al. Allergic rhinitis and adenoid hypertrophy in children: is adenoidectomy always really useful? J Biol Regul Homeost Agents. 2015;29(1):58-63.

Tatlıpınar A, Duman D, Uslu C, Egeli E. The effects of obstructive sleep apnea syndrome due to adenotonsillar hypertrophy on the cardiovascular system in children. Turk J Pediatr. 2011;53:359-63.

Orji FT, Adiele DK, Umedum NG, Akpeh JO, Ofoegbu VC, Nwosu JN. The clinical and radiological predictors of pulmonary hypertension in children with adenotonsillar hypertrophy. Eur Arch Otorhinolaryngol. 2017;274(3):1237-43.


Cincin A, Sakalli E, Bakirci EM, Dizman R. Relationship between obstructive sleep apnea-specific symptoms and cardiac function before and after adenotonsillectomy in children with adenotonsillar hypertrophy. Int J Pediatr Otorhinolaryngol. 2014;78(8):1281-7.


Kara CO, Ergin H, Koçak G, Kılıç Il, Yurdakul M. Prevalence of tonsillar hypertrophy and associated oropharyngeal symptoms in primary school children in Denizli, Turkey. Int J Pediatr Otorhinolaryngol. 2002;66(2):175-9.


Karaca CT, Toros SZ, Noseri H, Kulekci S, Kalayck C, Oysu C, et al. Role of allergy in children with adenotonsillar hypertrophy. J Craniofac Surg. 2012;23(6):e611-3.


Pereira L, Monyror J, Almeida FT, Almeida FR, Guerra E, Flores-Mir C, et al. prevalence of adenoid hypertrophy: A systematic review and meta-analysis. Sleep Med Rev. 2018;38:101-12.


Zhang X, Sun B, Li S, Jin H, Zhong N, Zeng G. Local atopy is more relevant than serum s Ig E in reflecting allergy in childhood adenotonsillar hypertrophy. Pediatr Allergy Immunol. 2013;24(5):422-6.


Venekamp RP, Hearne BJ, Chandrasekharan D, Blackshaw H, Lim J, Schilder AGM. Tonsillectomy or adenotonsillectomy versus non‐surgical management for obstructive sleep‐disordered breathing in children. Cochrane Database Syst Rev. 2015;2015(10): CD011165.

Lou Z. Adenoid hypertrophy in children and allergic rhinitis. Eur Arch Otorhinolaryngol. 2018;275(3):831-2.


Evcimik MF, Dogru M, Cirik AA, Nepesov MI. Adenoid hypertrophy in children with allergic disease and influential factors. Int J Pediatr Otorhinolaryngol. 2015;79(5):694-7.


Eren E, Arslanoglu S, Erdem SB, Nacaroglu T, Karkiner CS, Can D, et al. Chicken or the egg: the dilemma of allergic rhinitis versus adenoid hypertrophy. Rhinology. 2015;53(2):154-9.


Cho K-S, Kim SH, Hong S-L, Lee J, Mun SJ, Roh YE, et al. Local atopy in childhood adenotonsillar hypertrophy. Am J Rhinol Allergy. 2018;32(3):160-6.


Kuhle S, Hoffmann DU, Mitra S, Urschitz MS. Anti‐inflammatory medications for obstructive sleep apnoea in children. Cochrane Database Syst Rev. 2020;1(1):CD007074.

PMid:31978261 PMCid:PMC6984442

Kar M, Altıntoprak N, Muluk NB, Ulusoy S, Bafaqeeh SA, Cingi C. Antileukotrienes in adenotonsillar hypertrophy: a review of the literature. Eur Arch Otorhinolaryngol 2016;273(12):4111-7.


Kheirandish-Gozal L, Kim J, Goldbart AD, Gozal D. Novel pharmacological approaches for treatment of obstructive sleep apnea in children. Expert Opin Investig Drugs. 2013;22(1):71-85.


Sakarya E, Muluk NB, Sakalar E, Senturk M, Aricigil M, Bafaqeeh S, et al. Use of intranasal corticosteroids in adenotonsillar hypertrophy. J Laryngol Otol. 2017;131(5):384-90.


Chohan A, Lal A, Chohan K, Chakravarti A, Gomber S. Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children. Int J Pediatr Otorhinolaryngol. 2015;79(10):1599-608.


Zhang L, Mendoza‐Sassi RA, César JA, Chadha NK. Intranasal corticosteroids for nasal airway obstruction in children with moderate to severe adenoidal hypertrophy. Cochrane Database Syst Rev. 2008;2008(3):CD006286.

PMid:18646145 PMCid:PMC8923350

Criscuoli G, D'Amora S, Ripa G, Cinquegrana G, Mansi N, Impagliazzo N, et al. Frequency of surgery among children who have adenotonsillar hypertrophy and improve after treatment with nasal beclomethasone. Pediatrics. 2003;111(3):e236-8.


Ciprandi G, Varricchio A, Capasso M, Varricchio A, De Lucia A, Ascione E, et al. Intranasal flunisolide treatment in children with adenoidal hypertrophy. Int J Immunopathol Pharmacol. 2007;20(4):833-6.


Huang S-W, Giannoni C. The risk of adenoid hypertrophy in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2001;87(4):350-5.


Modrzyński M, Zawisza E. Frequency of adenoid hypertrophy in children with allergic diseases. Przegl Lek. 2003;60(5):322-4.

Joshua B, Bahar G, Sulkes J, Shpitzer T, Raveh E. Adenoidectomy: long-term follow-up. Otolaryngol Head Neck Surg. 2006;135(4):576-80.


Griffin JL, Ramadan HH, Adham RE. Prevalence of IgE-mediated hypersensitivity in children with adenotonsillar disease. Arch Otolaryngol Head Neck Surg. 1994;120(2):150-3.


Scadding G. Non‐surgical treatment of adenoidal hypertrophy: the role of treating IgE‐mediated inflammation. Pediatr Allergy Immunol. 2010;21(8):1095-106.


How to Cite
Sadeghi Shabestari, M., Jabbari Moghaddam, Y., Kalani, N., Brumdanpur, F., Dakhili Ardestani, A., & Sohrabpour, M. (2022). Treatment of Allergic Patients with Adenotonsillar Hypertrophy: Surgery Versus Medication Therapy. Galen Medical Journal, 11, e2317.
Original Article